Ozone major blood ozonation in the management of dermatomyositis: a case report

This case report describes the potential clinical benefit and safety of ozone major blood ozonation (O₃-MBO) in the treatment of glucocorticoid (GC)-dependent dermatomyositis.

The patient received an initial 15-day daily course of O₃-MBO (at a concentration of 80 μg/mL), followed by repeated cycles of 15-day treatment alternating with 15-day rest periods over approximately 15 months. Laboratory parameters and cutaneous lesion status were continuously monitored during the treatment period.

In the case presented, the patient added 15 days of O₃-MBO therapy and 15 days of rest as adjunctive therapy without increasing the hormone dosage, which was associated with reductions in serum levels of CK, AST, and ALT, healed the skin ulcers on the shoulders, normalized the skin, reduced the facial edema, and was associated with reduced corticosteroid-related side effects.

O₃-MBO may serve as a valuable adjunctive treatment for patients with corticosteroid dependence or refractory dermatological symptoms.